SCHEMBL256038

SCHEMBL256038

C#Cc1ccc(-c2ccc(F)cc2)cn1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACACB O00763 2/20 0.39
NPC1 O15118 2/20 0.36
RXFP1 Q9HBX9 1/20 0.36
PDGFRB P09619 1/20 0.36
PDGFRA P16234 1/20 0.36
TDO2 P48775 1/20 0.35
PYCR1 P32322 1/20 0.35
GRM5 P41594 2/20 0.35
MAPK14 Q16539 1/20 0.34
KDR P35968 2/20 0.33
ALDH1A1 P00352 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2C9 P11712 1/20 0.33
HPGD P15428 1/20 0.33
CYP2C19 P33261 1/20 0.33
RAB9A P51151 1/20 0.33
TEK Q02763 1/20 0.33
POLB P06746 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29549206 0.87 GRM5 (0.41) NPC1GRM5ALDH1A1HPGDRAB9A
SCHEMBL22533036 0.87 GRM5 (0.41) NPC1GRM5ALDH1A1HPGDRAB9A
SCHEMBL739869 0.83
SCHEMBL19385063 0.82 RAB9A (0.45) NPC1GRM5ALDH1A1RAB9ASMN1; SMN2
SCHEMBL12496522 0.80 CHEK1 (0.49) ACACBALDH1A1CYP1A2CYP3A4CYP2C9
SCHEMBL2322615 0.80 LTA4H (0.43) NPC1CYP1A2RAB9ASMN1; SMN2MAP4K4
SCHEMBL256022 0.80 GRM5 (0.41) ACACBNPC1PDGFRBPDGFRAGRM5
SCHEMBL23417029 0.76 KIF11 (0.47) NPC1GRM5ALDH1A1RAB9ATEK
SCHEMBL256035 0.76 MCHR1 (0.49) ACACBNPC1RXFP1PDGFRBPDGFRA
SCHEMBL753744 0.72 CYP2A6 (0.55) NPC1PDGFRBPDGFRAGRM5MAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2611771-B1 SUBSTITUTED HETEROARYL- AND ARYLALKYNYL BENZENE DERIVATIVES AS ACC-INHIBITORS FOR THE TREATMENT OF METABOLIC DISEASES BOEHRINGER INGELHEIM INT (DE) 2016-11-23 EP disclosed
US-8835472-B2 Compounds, pharmaceutical compositions and uses thereof BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-09-16 US disclosed
US-8835472-B2 Compounds, pharmaceutical compositions and uses thereof BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-09-16 US disclosed
US-20120214785-A1 New compounds, pharmaceutical compositions and uses thereof BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-08-23 US disclosed
US-20120214785-A1 New compounds, pharmaceutical compositions and uses thereof BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-08-23 US disclosed
WO-2012028676-A1 NEW COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120214785-A1 New compounds, pharmaceutical compositions and uses thereof ABCG2, PGA5, PDE6G ACACB 2257/4885NPC1 139/4885RXFP1 2509/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.